These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria.
Inactivated cell culture derived viral vaccines were immunogenic when administered to naïve pigs.
As catumaxomab is a nonhumanized chimeric antibody derived from mouse/rat IgG it is immunogenic when administered to humans.
Plant-produced VLPs were immunogenic when administered to animals [ 15], further justifying continuing research into the use of plants for producing heterologous proteins for vaccine use.
Preclinical studies showed that recombinant NVLPs are immunogenic when administered by the parenteral [ 29], oral [ 40, 41], and intranasal routes [ 42].
Furthermore, 4CMenB was immunogenic when administered in a schedule of 2, 3 and 4 months, an important finding given the high rates of MenB disease in the first 6 months of life.
In clinical trials DTPa-HBV-IPV/Hib is immunogenic when administered in a 3-dose primary schedule to premature infants (<37 weeks of gestation), with the majority of subjects achieving antibody concentrations consistent with seroprotection after vaccination.
Three formulations of the candidate combined DTPw-HBV-IPV/Hib vaccine were immunogenic when administered as a booster dose to healthy toddlers, with safety and reactogenicity profiles that resembled licensed DTPw-HBV/Hib co-administered with IPV.
pylori) antigens (Ag) capable to elicit a protective immune response in animal models have been identified, but these antigens have not been shown to be strongly immunogenic when administered to humans.
Given that the DNA prime - MVA boost vaccinations have proven superior to MVA vaccinations alone in animal models and in humans [7] [11], [24], [25], it is possible that ADMVA may be more immunogenic when administered in combination with other DNA or viral vectors.
